Literature DB >> 2398056

Tissue kallikrein-binding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats.

J Chao1, K X Chai, L M Chen, W Xiong, S Chao, C Woodley-Miller, L X Wang, H S Lu, L Chao.   

Abstract

Kallikrein-binding protein was purified to apparent homogeneity from rat serum by Affi-Gel Blue, DEAE-Sepharose CL-6B, Sephacryl S-200 chromatography, and preparative gel electrophoresis or high performance liquid chromatography. The purified protein migrates as a single band of 60 kDa in a sodium dodecyl sulfate-polyacrylamide gel under reducing conditions. It is an acidic protein with isoelectric points ranging from 4.2 to 4.6. The amino terminus of the binding protein is an Asp residue as determined by sequence analysis. It forms a 92-kDa sodium dodecyl sulfatestable complex with kallikrein with a t1/2 of 18 min. Western blot and radioimmunoassay showed a distribution of the kallikrein-binding protein in serum, urine, and various tissues with a 5-10-fold lower amount in spontaneously hypertensive rats (SHR) than in Wistar-Kyoto rats (WKY). A full length cDNA clone encoding the kallikrein-binding protein was isolated from a rat liver cDNA library by immunoscreening and the translated amino acid sequence matches the amino-terminal 29-amino acid sequence of the binding protein. The cDNA sequence shares 68.8% identity with human alpha 1-antichymotrypsin and is identical to that of a rat hepatic protein. Dot blot analysis shows that kallikrein-binding protein is expressed at high levels in the liver and at low levels in the lung, salivary gland, and kidney. Its mRNA level in the liver decreases by 2-fold after acute phase inflammation and is higher in male than in female rats. Genomic Southern blot analyses reveal restriction fragment length polymorphisms between SHR and WKY rats in the binding protein locus. The results indicate that rat kallikrein-binding protein belongs to the serpin superfamily and its level is significantly reduced in the spontaneously hypertensive rats.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2398056

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

Review 1.  Wnt pathway antagonists and angiogenesis.

Authors:  Bin Zhang; Jian-Xing Ma
Journal:  Protein Cell       Date:  2010-11-09       Impact factor: 14.870

2.  Human tissue kallikrein 1 gene delivery inhibits PDGF-BB-induced vascular smooth muscle cells proliferation and upregulates the expressions of p27Kip1 and p2lCip1.

Authors:  Hui-Zhen Yu; Liang-di Xie; Peng-li Zhu; Chang-sheng Xu; Hua-jun Wang
Journal:  Mol Cell Biochem       Date:  2011-09-30       Impact factor: 3.396

Review 3.  Protective Role of Kallistatin in Vascular and Organ Injury.

Authors:  Julie Chao; Grant Bledsoe; Lee Chao
Journal:  Hypertension       Date:  2016-07-18       Impact factor: 10.190

4.  Kallistatin is a potent new vasodilator.

Authors:  J Chao; J N Stallone; Y M Liang; L M Chen; D Z Wang; L Chao
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

5.  Kallistatin inhibits TGF-β-induced endothelial-mesenchymal transition by differential regulation of microRNA-21 and eNOS expression.

Authors:  Youming Guo; Pengfei Li; Grant Bledsoe; Zhi-Rong Yang; Lee Chao; Julie Chao
Journal:  Exp Cell Res       Date:  2015-07-05       Impact factor: 3.905

6.  Sialorphin, a natural inhibitor of rat membrane-bound neutral endopeptidase that displays analgesic activity.

Authors:  Catherine Rougeot; Michaël Messaoudi; Véronique Hermitte; Anne Gaëlle Rigault; Thierry Blisnick; Christophe Dugave; Didier Desor; François Rougeon
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-30       Impact factor: 11.205

7.  Pivotal role of JNK-dependent FOXO1 activation in downregulation of kallistatin expression by oxidative stress.

Authors:  Bo Shen; Lee Chao; Julie Chao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-01-15       Impact factor: 4.733

8.  Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis.

Authors:  Pengfei Li; Grant Bledsoe; Zhi-Rong Yang; Hongkuan Fan; Lee Chao; Julie Chao
Journal:  Immunology       Date:  2014-06       Impact factor: 7.397

9.  Inhibition of connective tissue growth factor overexpression in diabetic retinopathy by SERPINA3K via blocking the WNT/beta-catenin pathway.

Authors:  Bin Zhang; Kevin K Zhou; Jian-xing Ma
Journal:  Diabetes       Date:  2010-03-18       Impact factor: 9.461

10.  SERPINA3K prevents oxidative stress induced necrotic cell death by inhibiting calcium overload.

Authors:  Bin Zhang; Jian-xing Ma
Journal:  PLoS One       Date:  2008-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.